Highlights of This Issue 4477

SPECIAL FEATURES

CCR Translations

4479 Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?
Adam S. Crystal and Alice T. Shaw
See article p. 4682

4482 MicroRNA Dissects Out Dangerous Pancreatic Cysts from All the Rest
Ryan M. Thomas and Jason B. Fleming
See article p. 4713

CCR New Strategies

4485 New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
Marc Ladanyi, Marjorie G. Zauderer, Lee M. Krug, Tatsuo Ito, Robert McMillan, Matthew Bott, and Filippo Giancotti

CCR Perspectives in Drug Approval

4491 The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Elias Pean, Sigrid Klaar, Eva Gil Berglund, Tomas Salmonson, Jeannett Borregaard, Kenneth F. Hofland, Jens Ersbøll, Eric Abadie, Rosa Giuliani, and Francesco Pignatti

HUMAN CANCER BIOLOGY

4498 Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization
J. Jack Lee, Nan Chen, and Guosheng Yin

4508 Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not
Maurizio Scaltriti, Shaeenah Dawood, and Javier Cortes

4522 Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPs, and DAMPs
Charles M. Ludgate

4526 Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
Lawson Eng, Abul Kalam Azad, Steven Habbous, Vincent Pang, Wei Xu, Anke H. Maitland-van der Zee, Svetap Savas, Helen J. Mackay, Eitan Amir, and Geoffrey Liu

4538 Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions
James J. Steinhardt and Ronald B. Gartenhaus

4549 Survival Signals and Targets for Therapy in Breast Implant–Associated ALK–Anaplastic Large Cell Lymphoma
Melissa G. Lechner, Carolina Megiel, Connor H. Church, Trevor E. Angell, Sarah M. Russell, Bikki B. Sevell, Julie K. Jang, Garry S. Brody, and Alan L. Epstein

4560 Chromosome 5q Loss in Colorectal Flat Adenomas
Quirinus J.M. Voorham, Beatriz Carvalho, Mark A. van de Wiel, Ekaterina S. Jordanova, Bauke Ylstra, Martin Kliment, Heike Grabsch, Bjorn J. Rembacken, Tomio Arai, Adriaan P. de Bruïne, Silvia Sanduleanu, Philip Quirke, Chris J.J. Mulder, Manon van Engeland, and Gerrit A. Meijer
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4570</td>
<td>Identifying and Targeting <strong>ROS1</strong> Gene Fusions in Non-Small Cell Lung Cancer</td>
<td>Kurtis D. Davies, Anh T. Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi M. Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D. Ross Camidge, Marileila Varella-Garcia, and Robert C. Doebele</td>
</tr>
<tr>
<td>4580</td>
<td>Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation</td>
<td>Zhenfeng Duan, Jianming Zhang, Edwin Choy, David Harmon, Xianzhe Liu, Petur Nielsen, Henry Mankin, Nathanael S. Gray, and Francis J. Hornicek</td>
</tr>
<tr>
<td>4589</td>
<td>The Pivotal Role of Integrin $\beta_1$ in Metastasis of Head and Neck Squamous Cell Carcinoma</td>
<td>Dongsheng Wang, Susan M. Muller, A.R.M. Ruhul Amin, Donghai Huang, Ling Su, Zhongliang Hu, Mohammad Aminur Rahman, Sreenivas Nannapaneni, Lydia Koenig, Zhengjia Chen, Mourad Tighiouart, Dong M. Shin, and Zhuo G. Chen</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: PRECLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4612</td>
<td>Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6</td>
<td>Laura H. Tang, Tanupriya Contractor, Richard Clausen, David S. Klimstra, Yi-Chieh Nancy Du, Peter J. Allen, Murray F. Brennan, Arnold J. Levine, and Chris R. Harris</td>
</tr>
<tr>
<td>4621</td>
<td>Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model</td>
<td>Katharina Fraedrich, Jörg Schrader, Harald Ittrich, Gunhild Keller, Artur Gontarewicz, Verena Matzat, Arno Kromminga, Andrea Pace, Jürgen Moll, Michael Bläker, Ansgar W. Lohse, Dieter Horsch, Tim H. Brummendorf, and Daniel Benten</td>
</tr>
<tr>
<td>4633</td>
<td>Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma</td>
<td>Kari J. Brewer Savannah, Elizabeth G. Demicco, Kristelde Lusby, Markus PH. Ghdimil, Roman Belousoff, Eric Young, Yiqun Zhang, Kai-Lieh Huang, Alexander J. Lazar, Kelly K. Hunt, Raphael E. Pollock, Chad J. Creighton, Matthew L. Anderson, and Dina Lev</td>
</tr>
<tr>
<td>4646</td>
<td>Role of Hedgehog Signaling in Malignant Pleural Mesothelioma</td>
<td>Yandong Shi, Ubiratan Moura, Isabelle Opitz, Alex Soltermann, Hubert Rehrauer, Svenja Thies, Walter Weder, Rolf A. Stahel, and Emanuela Felley-Bosco</td>
</tr>
<tr>
<td>4669</td>
<td>Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma</td>
<td>Claire Fahre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Gülü Gürgün, Diana Cirstea, Yiguo Hu, Jiho Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu-Tzu Tai, Paul G. Richardson, Teru Hideshima, and Kenneth C. Anderson</td>
</tr>
<tr>
<td>4682</td>
<td>Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants</td>
<td>Johannes M. Heuckmann, Hyatt Balke-Want, Florian Malchers, Martin Peifer, Martin L. So, Mirjam Koker, Lydia Meder, Christine M. Lovly, Lukas C. Heukamp, William Pao, Ralf Küppers, and Roman K. Thomas</td>
</tr>
</tbody>
</table>

See commentary p. 4479

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4691</td>
<td>HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy</td>
<td>Kuen-Tyng Lin, Yi-Wei Wang, Chiung-Tong Chen, Chun-Ming Ho, Wen-Hui Su, and Yuh-Shan Jou</td>
</tr>
</tbody>
</table>

Downloaded from clincancerres.aacrjournals.org on April 14, 2017. © 2012 American Association for Cancer Research.
Epstein-Barr Virus Infection and Expression of B-cell Oncogenic Markers in HIV-Related Diffuse Large B-cell Lymphoma
Chun Chao, Michael J. Silverberg, Otoniel Martinez-Maza, Margaret Chi, Donald I. Abrams, Reina Haque, Hongbin D. Zha, Michelle McGuire, Lanfang Xu, and Jonathan Said

miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
Hanno Matthaei, Dennis Wylie, Maura B. Lloyd, Marco Dal Molin, Jon Kemppainen, Skye C. Mayo, Christopher L. Wolfgang, Richard D. Schulick, Laura Langfield, Bernard F. Andruess, Alex T. Adai, Ralph H. Hruban, Anna E. Szafranska-Schwarzbach, and Anirban Maitra

The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5’ and 3’ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
Rui Wang, Yunjian Pan, Chenguang Li, Haichuan Hu, Yang Zhang, Hang Li, Xiaoyang Luo, Jie Zhang, Zhaoyuan Fang, Yuan Li, Lei Shen, Hongbin Ji, David Garfield, Yihua Sun, and Haiquan Chen

A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy
Minying Zhang, Sourindra Maiti, Chantale Bernatchez, Helen Huls, Brian Rabinovich, Richard E. Champlin, Luis M. Vence, Patrick Hwu, Laszlo Radvanyi, and Laurence J.N. Cooper

CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis
Tao Fu, Emmanouil P. Pappou, Angela A. Guzzetta, Jana Jeschke, Ruby Kwak, Pujan Dave, Craig M. Hooker, Richard Morgan, Stephen B. Baylin, Christine A. Jacobuzzo-Donahue, Christopher L. Wolfgang, and Nita Ahuja

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Yu Imamura, Terpei Morikawa, Xiaoyun Liao, Paul Lochhead, Aya Kuchiba, Mai Yamauchi, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Kevin M. Haigis, Charles S. Fuchs, and Shuji Ogino

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Andres Cervantes, Elena Elez, Desamparados Roda, Jeffrey Ecsedy, Teresa Macarulla, Karthik Venkatakrishnan, Susana Roselló, Jordi Andreu, JungAh Jung, Juan Manuel Sanchis-Garcia, Adelaida Piera, Inma Blasco, Laura Maños, José-Alejandro Pérez-Fidalgo, Howard Fingert, Jose Baselga, and Josep Tabernero

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
E. Claire Dees, Roger B. Cohen, Margaret von Mehren, Thomas E. Stinchcombe, Hua Liu, Karthik Venkatakrishnan, Mark Manfredi, Howard Fingert, Howard A. Burris III, and Jeffrey R. Infante

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
### Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors


### First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors


### A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer


### A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma


### Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid


### Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Jooeun Bae, Robert Smith, John Daley, Naoya Mimura, Yu-Tzu Tai, Kenneth C. Anderson, and Nikhil C. Munshi

### LETTER TO THE EDITOR

Nicola Personeni, Lorenza Rimassa, and Armando Santoro

### ABOUT THE COVER

Wright–Giemsa-stained cytospin of early passages of TLBR-2 cells in culture. This cell line derived from an aggressive breast implant–associated T-cell CD30⁺ ALK⁺ anaplastic large cell lymphoma (ALCL) shows typical morphologic features, including enlarged nuclei with frequent mitotic figures, multiple prominent nucleoli, pale cytoplasm with vesiculation, and occasional multinucleated giant cells (original magnification, ×400). Along with TLBR-1 and -3, it represents a new model for breast implant–associated ALCL and is characterized by a near triploid karyotype, specific chemotherapy drug sensitivities, and high expression of several pathway signals including Notch1, survivin, antiapoptotic genes, IL-6 and IL-2 autocrine cytokines, and STAT3, which seem to be associated with the oncogenesis and growth for these unique cancers. For details, see the article by Lechner and colleagues on page 4549 of this issue.